Lebut Jordane, Mourvillier Bruno, Argy Nicolas, Dupuis Claire, Vinclair Camille, Radjou Aguila, de Montmollin Etienne, Sinnah Fabrice, Patrier Juliette, Le Bihan Clément, Magalahes Eric, Smonig Roland, Kendjo Eric, Thellier Marc, Ruckly Stéphane, Bouadma Lila, Wolff Michel, Sonneville Romain, Houzé Sandrine, Timsit Jean-François
AP-HP, Bichat Hospital, Medical and Infectious Diseases ICU (MI2), University of Paris, IAME, INSERM U1137 (IAME), 75018, Paris, France.
Longjumeau Hospital, ICU, Longjumeau, France.
Ann Intensive Care. 2020 Feb 12;10(1):21. doi: 10.1186/s13613-020-0634-4.
In France, the incidence of severe imported malaria cases increased since early 2000. Artesunate was available (temporarily use authorization) since mid-2011 in France and commonly used for severe malaria since early 2013. Thus, the study objectives were to describe the patients with severe imported malaria admitted in intensive care unit (ICU) and assess the changes in clinical presentation and outcomes before and after this date.
Retrospective observational single-center study in the infectious diseases ICU of a referral university hospital, conducted on patients admitted for severe imported malaria from 2004 to 2017. Demographic variables, severity scores, WHO's severity criteria on admission, treatment, and ICU and hospital lengths of stay were collected. Patients' characteristics and outcomes were compared between both periods. A poor outcome was defined as the composite endpoint of death, or requirement for vasopressors, invasive mechanical ventilation and/or renal replacement therapy.
189 patients were included, 98 in 2004-2012 and 91 in 2013-2017, most often from West and Central African countries (96%). The number of WHO criteria for severe malaria was comparable in both groups, but SAPS II, SOFA and ICU length of stay were significantly higher in 2004-2012, while patients of African origin living in France were less frequent (p < 0.01). The outcome was poor for 41/98 cases in 2004-2012 and 12/91 cases in 2013-2017 (p < 0.01). The risk factors of poor outcome on the multivariate logistic regression were a neurological failure (adjusted odds ratio (adjOR = 3.23; 95% CI (1.03-10.08), p = 0.004), cardio-circulatory failure (adjOR = 9.92; 95% CI (2.34-42), p = <0.01) and creatinine blood levels > 265 µmol/L (adjOR = 10.76; 95% CI (3.17-36.53), p < 0.01). In the multivariate analysis, IV artesunate was not associated with a better outcome. Patients of African origin did not seem to have a better outcome than Caucasian patients or those from other origins (adjOR = 0.59; 95% CI (0.21-1.65), p = 0.31).
Patients with imported malaria admitted in ICU in 2013-2017 were less severely ill than those in 2004-2012. These trends could be partially explained by the increasing proportion of African patients visiting friends or relatives or living in endemic areas.
在法国,自2000年初以来,严重输入性疟疾病例的发病率有所上升。青蒿琥酯自2011年年中起在法国可供使用(临时使用授权),自2013年初起常用于治疗严重疟疾。因此,本研究的目的是描述入住重症监护病房(ICU)的严重输入性疟疾病例,并评估该日期前后临床表现和结局的变化。
在一所转诊大学医院的传染病重症监护病房进行回顾性观察单中心研究,研究对象为2004年至2017年因严重输入性疟疾入院的患者。收集人口统计学变量、严重程度评分、入院时世界卫生组织的严重程度标准、治疗情况以及ICU和住院时间。比较两个时期患者的特征和结局。不良结局定义为死亡、需要使用血管升压药、有创机械通气和/或肾脏替代治疗的复合终点。
共纳入189例患者,2004 - 2012年98例,2013 - 2017年91例,大多数患者来自西非和中非国家(96%)。两组严重疟疾的世界卫生组织标准数量相当,但2004 - 2012年的简化急性生理学评分II(SAPS II)、序贯器官衰竭评估(SOFA)和ICU住院时间显著更高,而居住在法国的非洲裔患者较少(p < 0.01)。2004 - 2012年41/98例患者结局不良,2013 - 2017年为12/91例(p < 0.01)。多因素逻辑回归分析显示,不良结局的危险因素为神经功能衰竭(调整比值比(adjOR)= 3.23;95%置信区间(CI)(1.03 - 10.08),p = 0.004)、心循环衰竭(adjOR = 9.92;95% CI(2.34 - 42),p = <0.01)和血肌酐水平> 265 μmol/L(adjOR = 10.76;95% CI(3.17 - 36.53),p < 0.01)。在多因素分析中,静脉注射青蒿琥酯与更好的结局无关。非洲裔患者的结局似乎并不比白种人患者或其他种族患者更好(adjOR = 0.59;95% CI(0.21 - 1.65),p = 0.31)。
2013 - 2017年入住ICU的输入性疟疾病例病情不如2004 - 2012年严重。这些趋势可能部分归因于探亲访友或生活在流行地区的非洲患者比例增加。